
Biotechnology
Innovations in cancer immunotherapy: Bi-specific T cell engagers
Bi-specific T cell engagers are poised to become key immunotherapy treatments due to simpler production and new safety advances.
The white paper has been sent to the email address you provided. You can download it directly by clicking the button below.
For more information, please visit CAS Custom ServicesSM.



